Qyuns Therapeutics Announces Milestone Payment from Roche for QX031N Clinical Progress
Key Points of the Announcement
- Milestone Payment Triggered: Qyuns Therapeutics Co., Ltd. has received a milestone payment from F. Hoffmann-La Roche Ltd (“Roche”) following the dosing of the first participant in the Phase I clinical trial of QX031N.
- Clinical Trial Initiated: The Phase I trial of QX031N (also known as RG6981) commenced in New Zealand. The first participant was dosed on March 27, 2026.
- Trial Design: The study is a randomized, investigator- and participant-blind, placebo-controlled, single- and multiple-dose escalation, parallel-group trial. It aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of QX031N in three populations: healthy participants, those with chronic obstructive pulmonary disease (COPD), and those with asthma.
- Collaboration with Roche: Qyuns Therapeutics entered into a global exclusive collaboration and license agreement with Roche on October 28, 2025, granting Roche the exclusive right to develop, manufacture, and commercialize QX031N worldwide.
- Drug Profile: QX031N is a clinical-stage long-acting bispecific antibody targeting human thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33)—proteins involved in respiratory diseases and inflammation.
- Potential Market Impact: QX031N is positioned to become a “First-in-class” and “Best-in-disease” therapy for COPD and asthma, which could significantly enhance its commercial potential and the future value of Qyuns Therapeutics.
Shareholder Information & Potential Price Sensitivity
- This milestone payment from Roche represents tangible progress in the global collaboration and signals Roche’s commitment to the development of QX031N.
- The initiation of the first-in-human clinical trial marks a key inflection point in the drug’s development, potentially increasing investor confidence in Qyuns Therapeutics’ pipeline.
- The exclusivity agreement with Roche could lead to further milestone payments, royalties, and commercial opportunities, directly impacting future revenue streams and valuation.
- The advancement of QX031N as a potential “First-in-class” therapy for major respiratory diseases increases the company’s profile in the biotech sector and could stimulate positive momentum in the share price.
- Investors should monitor clinical trial outcomes and further announcements regarding regulatory progress or additional payments from Roche.
Additional Details
- Board Composition: The Board is led by Mr. Qiu Jiwan (Chairman and Executive Director) and includes other executive, non-executive, and independent directors.
- Trial Locations: The initial trial is conducted in New Zealand, focusing on three key patient groups.
- Scientific Rationale: Targeting TSLP and IL-33 addresses alarmins released due to allergens, pollution, viruses, and mechanical stimuli, making QX031N a strong candidate for diseases with high unmet medical needs.
- Date of Payment: The milestone payment was received on May 27, 2026.
Disclaimer
The information presented is based on the latest voluntary announcement by Qyuns Therapeutics Co., Ltd. Investors should note that clinical development and collaboration agreements carry inherent risks and uncertainties. Share price movements may be influenced by trial outcomes, regulatory decisions, and further collaboration developments. This article does not constitute investment advice. Please consult a professional financial advisor before making investment decisions.
Qyuns Therapeutics 收到羅氏里程碑付款，QX031N臨床進展
公告重點
- 里程碑付款： Qyuns Therapeutics有限公司因首位受試者於QX031N第一階段臨床試驗中成功用藥，收到F. Hoffmann-La Roche Ltd（羅氏）支付的里程碑款項。
- 臨床試驗啟動： QX031N（亦稱RG6981）第一階段臨床研究已在新西蘭展開，首位受試者於2026年3月27日完成用藥。
- 試驗設計： 該研究為隨機、研究者與受試者雙盲、安慰劑對照、單/多劑量遞增、並行組研究。旨在評估QX031N於健康人、慢阻肺（COPD）患者及哮喘患者的安全性、耐受性、藥物動力學及藥效學。
- 羅氏合作協議： Qyuns Therapeutics於2025年10月28日與羅氏簽訂全球獨家合作及授權協議，羅氏獲得QX031N全球獨家開發、製造及商業化權利。
- 藥物特點： QX031N為臨床階段長效雙特異性抗體，靶向人類胸腺基質淋巴細胞生成素（TSLP）及白介素33（IL-33），兩者均為與呼吸疾病及炎症相關的重要蛋白。
- 市場潛力： QX031N有望成為慢阻肺及哮喘領域的「同類首創」及「最佳療效」藥物，提升公司商業價值及未來估值。
股東須知及潛在價格敏感資訊
- 羅氏支付里程碑款項，反映全球合作取得實質進展，並展現羅氏對QX031N開發的承諾。
- 首次人體臨床試驗啟動，標誌藥物研發的關鍵節點，有望提升投資者對Qyuns Therapeutics研發管線的信心。
- 與羅氏的獨家協議未來或帶來更多里程碑款項、權利金及商業機會，直接影響收入及估值。
- QX031N成為慢阻肺及哮喘「同類首創」藥物，有望提升公司在生物科技行業地位，刺激股價正面動力。
- 投資者應關注臨床試驗結果及後續公告，包括監管進展或羅氏進一步付款。
其他詳情
- 董事會組成： 現任董事會主席兼執行董事邱繼萬先生，另有多位執行、非執行及獨立非執行董事。
- 試驗地點： 初步臨床試驗於新西蘭進行，聚焦三類受試者。
- 科學依據： 靶向TSLP及IL-33，針對因過敏原、污染、病毒及機械刺激釋放的alarmin蛋白，對高未被滿足需求疾病具潛力。
- 付款日期： 里程碑款項於2026年5月27日收到。
免責聲明
本資訊根據Qyuns Therapeutics最新自願公告整理。投資者須注意，臨床開發及合作協議存在風險與不確定性，股價或受試驗結果、監管決策及合作進展影響。本文不構成投資建議，投資前請諮詢專業人士。
